Celyad Oncology S.A.
Celyad Oncology S.A. (CLYYF) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
clyyf · stock forecast · 4 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.25
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.25 | ↓ 0.60% |
1-day model range: $0.25–$0.25. Peak: $0.25 (-0.60%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · CLYYF · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-01-10 | Wells Fargo | Maintains | Overweight→Overweight |
| 2021-08-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-05-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-03-25 | JonesTrading | Downgrade ↓ | Buy→Hold |
| 2020-12-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2020-03-25 | Wells Fargo | Maintains | Overweight→Overweight |
| 2020-03-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2016-07-04 | UBS | Downgrade ↓ | Buy→Neutral |
| 2015-08-25 | UBS | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Celyad Oncology S.A. (CLYYF) stock. Of the recent 9 rating actions, 0 were upgrades and 2 were downgrades. 4 analysts currently cover CLYYF.
Analyst Recommendation Trends
CLYYF analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 99.4% YoY
Revenue Next Year
$2M
↑ 24474.7% YoY
EPS This Year
$-2.26
EPS Next Year
$-2.20
↓ 2.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast CLYYF EPS of $-2.26 for the current fiscal year, based on estimates from 1 analysts. The CLYYF revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CLYYF stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CLYYF price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The CLYYF short-term stock prediction for tomorrow is $0.25 (-0.60%).
Celyad Oncology S.A. trades on OTC under the ticker CLYYF. The CLYYF stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
CLYYF forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month CLYYF price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.25.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.